RxDoctor Payments Data

Duane Nii, MD

Ophthalmology · Fresno, CANPI 1346463460

Payments from drug & device makers

$224in general payments, 2019–2025

Across 11 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Oyster Point Pharma, Inc.$35
  • Biotissue Holdings Inc.$35
  • Thea Pharma Inc.$30
  • Tarsus Pharmaceuticals, Inc.$28
  • Glaukos Corporation$24
  • Bausch & Lomb Americas Inc.$23
  • plus $50 from 3 others

What the payments were for

  • Food & beverage$224100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$224 in reported general payments places this provider in the 20th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$93,286
Medicare patients
369
Services billed
1,026

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine102$85,203
LumiganBimatoprost109$47,352
VyzultaLatanoprostene Bunod85$41,838
XiidraLifitegrast30$31,413
RhopressaNetarsudil Mesylate47$20,746
RocklatanNetarsudil Mesylat/Latanoprost43$18,090
SimbrinzaBrinzolamide/Brimonidine Tart60$14,700
Cyclosporine37$14,116
MieboPerfluorohexyloctane/Pf17$12,238
Betoptic SBetaxolol Hcl19$8,301
Brimonidine Tartrate136$6,803
EysuvisLoteprednol Etabonate11$5,496
TafluprostTafluprost/Pf24$4,302
Alphagan PBrimonidine Tartrate14$3,857
Travoprost43$3,838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$16$136,412225 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo$23$85,490132 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$18$38,83690 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →